Personalized Medicine Market Analysis, Size, Share & Growth Forecast 2026–2034

Companion Diagnostic Regulatory Co-Development Requiring PMA Submission Alongside NDA or BLA Has Established the Biomarker-Drug Approval Model That Ensures Targeted Therapies Are Used Only in the Patient Populations That Clinical Trials Demonstrated Benefit For.Guardant Health's Guardant360 and Foundation Medicine's FoundationOne Liquid CDx have together generated over 400,000 annual liquid biopsy tests in oncology as companion diagnostics for targeted therapy selection in NSCLC, breast, and colorectal cancer, establishing cell-free DNA analysis as a routine component of advanced cancer management. Natera's Signatera MRD assay and Guardant Health's Shield multi-cancer early detection test represent the extension of liquid biopsy from treatment guidance into surveillance and screening applications where the commercial markets are an order of magnitude larger than the companion diagnostic indication. The analytical validation standards for liquid biopsy clinical utility including sensitivity, specificity, and positive predictive value at relevant ctDNA allele fractions have been codified by ACMG and NCCN guidance that enables clinical laboratory adoption and payer reimbursement policy development.

Polygenic Risk Score Expanding Beyond Single-Variant Biomarkers to Aggregate Thousands of Common Variants Is Enabling Preventive Intervention Prioritisation for High-Genetic-Risk Individuals Before Clinical Risk Factors That Standard Calculators Identify Have Manifested.Foundation Medicine's CDx assay measuring TMB from whole-exome-equivalent sequencing enabled the FDA TMB-high tumour-agnostic pembrolizumab label for solid tumours with TMB above 10 mutations per megabase, establishing comprehensive genomic profiling as necessary for the subset of patients whose tumour may respond to checkpoint therapy independent of histology. The clinical limitation of TMB as a checkpoint predictive biomarker is the heterogeneity of response across tumour types where TMB is a useful but imperfect predictor compared with MSI-high status, and NCCN guidance recommends CGP as broadly applicable rather than TMB testing in isolation. The commercial consequence of TMB-based tumour-agnostic approval is the mandate for CGP testing in any solid tumour patient being considered for pembrolizumab, driving Foundation Medicine's CDx volume across tissue types that previously generated no molecular testing demand.

Pharmacogenomics CYP2C19, DPYD, and TPMT EHR Clinical Decision Support Alerts at Prescribing Are Enabling Genotype-Guided Dosing That Prevents Adverse Events in Poor Metabolisers and Therapeutic Failure in Ultra-Rapid Metabolisers.CPIC guideline endorsement of CYP2D6 testing before tamoxifen prescribing in ER-positive breast cancer and DPYD testing before fluorouracil administration in colorectal cancer has driven clinical laboratory test volume from single-gene assays to multi-gene pharmacogenomic panels from Myriad GenomicHealth, GeneDx, and Admera Health that test 25-50 drug metabolism genes simultaneously. The PREDICT programme at Vanderbilt University Medical Centre and AgeNT programme in the Netherlands demonstrate that pre-emptive pharmacogenomic panel testing followed by results integration into electronic health record clinical decision support alerts reduces adverse drug event rates by 20-30% compared with reactive single-gene testing at drug initiation. The economic model for pre-emptive pharmacogenomic testing requires healthcare systems to absorb upfront panel test cost for downstream drug cost and adverse event savings that accrue over multiple medication episodes, and value demonstration studies from Vanderbilt and Harvard Pilgrim Health Care are informing payer coverage policy for multi-gene pre-emptive pharmacogenomic programmes.

For related market intelligence, see the Precision Medicine Market.